Corvaltab
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Analogs
- 9. Terms and conditions of storage
- 10. Terms of dispensing from pharmacies
Korvaltab is a drug with a vasodilator, sedative and moderate antispasmodic effect.
Release form and composition
Korvaltab is produced in the form of tablets: round, flat, with chamfers, almost white or white interspersed, with a specific smell (10 pcs. In blisters, 2 or 10 blisters in a cardboard box).
The composition of 1 tablet contains active ingredients:
- Phenobarbital - 7.5 mg;
- Ethyl ester of alpha-bromisovaleric acid - 8.2 mg;
- Peppermint oil - 0.58 mg.
Auxiliary components: magnesium stearate, microcrystalline cellulose, potato starch, beta-cyclodextrin, lactose monohydrate.
Indications for use
- Neuroses with increased irritability;
- Hypertension and vegetative-vascular dystonia (along with other drugs);
- Insomnia;
- Tachycardia, mild spasm of the coronary vessels;
- Intestinal cramps associated with neurovegetative disorders (as an antispasmodic).
Contraindications
- Hepatic porphyria;
- Severe functional disorders of the kidneys and / or liver;
- Severe heart failure;
- Children's age (due to the lack of experience with the use of Corvaltab in this age group of patients);
- Hypersensitivity to drug components.
Medicines containing phenobarbital are contraindicated for use in diabetes mellitus, acute myocardial infarction, severe arterial hypotension, depression, alcoholism, myasthenia gravis, drug and drug addiction, obstructive syndrome, respiratory diseases with shortness of breath.
Korvaltab is not prescribed to lactating and pregnant women.
Since the drug contains lactose, patients with hereditary lactose-galactose intolerance are not recommended to take it.
Corvaltab should be taken with caution in patients with arterial hypotension, hyperkinesis, hyperthyroidism, adrenal hypofunction, acute and persistent pain, acute drug intoxication.
Method of administration and dosage
Corvaltab is taken orally, before meals.
The dosage and duration of the treatment course is set by the doctor individually.
As a rule, Corvaltab is prescribed 2-3 times a day, 1-2 tablets. A single dose increased to 3 tablets is used in the treatment of spasms of the coronary vessels and tachycardia.
Side effects
Corvaltab is usually well tolerated.
In some cases, the following side effects may develop:
- Nervous system: weakness, fatigue, decreased concentration of attention, ataxia, nystagmus, paradoxical agitation, impaired coordination of movement, hallucinations, lethargic reactions, drowsiness, cognitive impairment, confusion, headache, light dizziness;
- Digestive system: feeling of heaviness in the epigastric region, constipation, with prolonged use - vomiting, nausea, liver functional disorders;
- Cardiovascular system: bradycardia, arterial hypotension;
- Musculoskeletal system: with prolonged use - violation of osteogenesis;
- Hematopoietic system: thrombocytopenia, anemia, agranulocytosis;
- Immune system: hypersensitivity reactions, including allergic reactions (skin rash, itching, urticaria), angioedema;
- Skin and mucous membranes: toxic epidermal necrolysis, Stevens-Johnson syndrome;
- Others: shortness of breath.
Long-term use of drugs containing bromine can lead to bromine poisoning, characterized by symptoms such as: depressed mood, depression of the central nervous system, ataxia, apathy, confusion, conjunctivitis, lacrimation, rhinitis, purpura, or acne.
Usually, these side effects disappear when the dose of Corvaltab is reduced or therapy is stopped.
special instructions
During treatment, alcohol consumption should be avoided.
Phenobarbital, which is part of Corvaltab, can lead to the risk of developing Stevens-Johnson and Lyell's syndrome (most likely in the first weeks of use).
Long-term therapy is not recommended, since long-term administration of the drug can cause drug dependence, accumulation of bromine in the body and, as a result, poisoning with it.
In cases where pain in the heart area does not go away after taking Corvaltab, you need to consult a doctor to exclude acute coronary syndrome.
Corvaltab can cause dizziness and drowsiness, therefore, during the period of therapy, patients are not recommended to work with dangerous mechanisms, drive vehicles and perform work that requires quick motor and mental reactions and increased attention.
Drug interactions
With the simultaneous use of Korvaltab with certain drugs, undesirable effects may occur:
- Medicines that depress the central nervous system: mutual enhancement of action;
- Analgesics, local anesthetic drugs: enhancing their action;
- Valproic acid preparations, alcohol: strengthening the action of Corvaltab;
- Medicines that are metabolized by liver enzymes (including monoamine oxidase inhibitors): prolongation of the effect of phenobarbital;
- Rifampicin: reducing the effect of phenobarbital;
- Gold preparations: increased risk of kidney damage;
- Cardiac glycosides, indirect anticoagulants, antiviral, antimicrobial, antifungal, oral hypoglycemic, antiepileptic, psychotropic, anticonvulsant, immunosuppressive, hormonal, antiarrhythmic, cytostatic, antihypertensive drugs): accelerating their metabolism;
- Non-steroidal anti-inflammatory drugs (long-term simultaneous use): increased risk of bleeding and gastric ulcer formation;
- Zidovudine: increased toxicity of both drugs;
- Methotrexate: increased toxicity.
Analogs
Korvaltab's analogues are: Barboval, Valocordin, Valeckard, Korvaldin, Corvalcaps.
Terms and conditions of storage
Keep out of reach of children at temperatures up to 25 ° C.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Available without a prescription.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
